Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
225Ac-FAP-VG-02
- Development stage
- Preclinical
- Lead developer
- VitsGen Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
225Ac-FAP-VG-02 is a radionuclide drug conjugate (RDC) being developed by VitsGen Therapeutics for the treatment of tumors expressing fibroblast activation protein (FAP). The drug consists of a targeting moiety specific for FAP conjugated to the alpha-emitting radioisotope Actinium-225. FAP is highly expressed in the cancer-associated fibroblasts (CAFs) of the tumor microenvironment in various solid tumors. By targeting FAP, 225Ac-FAP-VG-02 delivers potent alpha-particle radiation directly to the tumor site, inducing double-strand DNA breaks and subsequent cell death in both FAP-positive cells and neighboring tumor cells via the bystander effect. It is currently in the preclinical stage of development.
- Other names
- Actinium-225 FAP-VG-02Actinium225 FAP-VG-02Actinium 225 FAP-VG-02
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 225Ac-FAP-VG-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 225Ac-FAP-VG-02.